Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

MLSCI 475 > Transplantation Immunology > Flashcards

Transplantation Immunology Flashcards

1
Q

define xenograft

A

transplantation from one species to another

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

why transplant?

A

treatment of variety of medical conditions, such as end-stage organ failure, chronic diseases, malignancies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

T or F. Transplantation is more expensive than dialysis for patients while improving quality of life

A

F! it’s less expensive and improves quality of life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

sources of stem cell transplants

A

bone marrow
peripheral blood
umbilical cord blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

trnasplantation antigens

A

MHC = HLA (proteins)

ABO blood group antigens = carb structures on surface of RBCs & endothelium; indivs produce natural antibodies to non-self ABO antigens

minor histocompatibility antigens
- immunogenic peptides derived from polymorphic self proteins
- autoantigens, male-specific antigens (H-Y)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

cell surface proteins that present peptides of endogenous/exogenous antigens to T cells

A

MHC/HLA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

6 clinically relevant HLA loci

A

HLA-A, -B, -C, -DR, -DQ, -DP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Class I HLA

A

HLA - A,-B,-C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

function of HLA

A

presentation of peptides to T cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

why is HLA so diverse?

A

needed so we are able to deal with all pathogens that may be encountered
- HLA molecules highly polymorphic
- co-dominant expression of parental HLA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

T or F. HLA polymorphism is focused around the peptide binding region

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

HLA polymorphism allows for the presentation of different repertoires of ____________ to __ cells

A

peptides; T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

why not HLA match every donor?

A

due to HLA diversity it is difficult to find 0 MM donor

demand of organs higher than available supply
on average, 250 Canadians die each year while waiting
god graft survival is possible without matching using modern immunosuppressive drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

how do B cells identify HLA antigens?

A
  • recognize epitopes on surface of antigens
  • various molecular compositions (proteins, lipids, carbs, DNA, etc.)
  • soluble as well as membrane-associated antigens
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

how do T cells recognize HLA antigens

A

epitopes buried within antigens (must be broken down first to fragments)
peptide:MHC molecule complex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

two branches of antibody-mediated rejection

A

complment-mediated cytotoxicity

antibody-dependent-cell-mediated toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

C4d role in antibody-mediated rejection

A

byproduct of complement cascade
- deposited in cell membrane
- used clinically to assess whether pt is having Ab-mediated rejection
- can stain for it = green colour

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

pre-formed antibodies present that bind to the graft endothelium right after trnasplantation

A

hyperacute rejection
- occurs within mins/hrs
- RARE bc we screen for Abs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

acute cellular rejection

A

T cells destroys the graft parenchyma (and vessels) by toxicity and inflammatory rxns
- takes weeks (early) or delayed (months <1 yr)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

acute humoral rejection

A

antibodies damage graft vasculature
- early (weeks; often memory response!) or delayed (months; memory response vs de novo antibodies)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

T or F. Immunological memory also applies to HLA antigens

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

T or F. The majority of transplantation rxns we see now are chronic rejections

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Define chronic rejections

A
  • caused by both humoral and cellular immunity
  • intimal thickening and fibrosis of graft vessels as well as graft atrophy
  • time = late (months to years)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

HLA inheritance

A

Mendelian
- 1 haplotype from mother
- 1 haplotype from father
- antigens are codominantly expressed = homozygous or heterozygous

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

T or F. HLA diversity is an evolutionary advantage

A

T!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

T or F. Homozygous individuals feature more HLA types

A

F! Heterozygotes do = target more antigens and on average better protected (selective advantage)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

T or F. Hosts with rare HLAs better protected (selective advantage)

A

T! HLA helps eliminate pathogens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

T or F. HLA-mismatched couples more fertile

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

T or F. HLA presents a challenge in transplantation

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

T or F. ONLY donor-derived HLA peptides that are different from self-HLA peptides will be recognized as foreign = immune response

A

T!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

describe the direct pathway of allorecognition by intact donor HLA

A

intact dono HLA presented to recipient T cells by donor APCs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

on of the leading causes of graft loss

A

allograft rejection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

induction therapy

A

administered pre-translpant or in the peri-transplant period

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

maintenance therapy

A

basal immunosuppressive drugs given continuously long term

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

rescue therapy

A

therapies given during rejection episodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

the different immunosuppressive drugs over time

A

induction therapy
maintenance therapy
rescue therapy

37
Q

types of immunosuppressive drugs

A

glucocorticosteroids

small molecule drugs

protein-based/biologic drugs

38
Q

examples of glucocorticosteroids

A

prednisone - maintenance therapy

methylprednisolone - resuce therapy

39
Q

broad spectrum immunosuppressive and anti-inflammatory effects

A

glucocorticosteroids

40
Q

these drugs act intracellularly, mainly used for maintenance therapy, and inhibit pathways downstream of cell activation

A

small molecules drugs

41
Q

focus of smalll molecule drigs

A

mainly on inhibiting cell activation and/or proliferation

42
Q

calcineurin inhibitors (CNIs)

A

cyclosporine, tacrolimus (small molecules)
- inhibition of transcription factors required for growth factor production and expression of growth factor receptors
- decreases B and T cell activation
- most commonly used as maintenance therapy

43
Q

purine synthesis inhibitors

A

azathioprine, mycophenolate mofetil (MMF) (small molecules)
- inhibition of DNA synthesis
- decreased B and T cell clonal expansion
- commonly used along CNIs as maintenance therapy

44
Q

mTOR inhibitors

A

mammalian target of rapamycin
- sirolumus/rapamycin, evrolimus
(small molecules)

  • inhibits mTOR
  • limits response to growth factors (anti-neoplastic)
  • decreases T and B cell clonal expansion
  • becoming more common as maintenance therapy in CNI sparing protocols
45
Q

describe trough levels

A

the lowest concentration reached by a drug before next dose is administered

46
Q

descibe protein based or biologic drugs

A
  • mainly for induction and rescue therapy
  • act extracellularly
  • receptor-ligand or antibodies
47
Q

advantages of protein-based/biologic drugs

A

high specificity, particularly monoclonal Abs and fusion proteins

low toxicity, a least from the agent itself

long half-life in circulation, same as IgG molecules (~3 weeks)

48
Q

disadvantages of protein-based/biologic drugs

A

some interfere with antibody detection assays and/or flow cytometry XM
- cost!

49
Q

processes to remove antibodies

A

plasmapheresis
IVIg

50
Q

plasmapheresis

A

process that filters the blood and removes harmful antibodies

51
Q

Intravenous immunoglobulin

A

pooled immunoglobulins (IgG) from the plasma of approx. a thousand or more blood donors

inhibition of
- Ab production
- complement activation
- immune cell activation

52
Q

class I HLA

A

A, B, C
- polymorphic monomor w B2 microglobulin
- all nucleated cells + PLTs
- expression levels vary = high in lymphs

53
Q

class II HLA

A

DR, DQ, DP
- heterodimer of polymorphic a and B chains
- APCs only
- can be upregulated on other cells

54
Q

alloantigen recognition by T cells (3)

A

direct
indirect
semi-direct pathway

55
Q

describe the indirect pathway of allorecognition

A
  • peptides from donor HLA
  • presented to recipient T cells by recipient APCs
  • like how adaptive immune responses to foreign peptides

NOTE: only donor-derived HLA peptides different from self HLA will be recognized as foreign

56
Q

describe the direct pathway of allorecognition

A
  • APCs are from donor; travelled with organ when transplanted or activated endothelial cells (upregulated HLA)
  • intact donor HLA presented to recipient T cells by donor APCs
  • unique to transplantation
  • greater immune response than indirect pathway
57
Q

describe the semi-direct pathway of allorecognition

A
  • donor cells can secrete exosomes/vesicles; also happens with inflammation or when cells are damaged; can be in circulation = have HLA molecules in surface; can morph with recipient APCs (direct presentation but with recipient APCs)
58
Q

antibody cross-reactivity

A

individuals exposd to just one antigen that contains an epitope… can make Abs to all antigen with that same epitope

59
Q

two main types of allograft rejection

A

T-cell mediated rejection (TCMR)
antibody-mediated rejection (AMR)

60
Q

this is the first to occur if there is rejection

A

T-cell mediated rejection

61
Q

what happens in T cell-mediated rejection

A

donor and recipient APCs migrate to secondary lymphoid organs

APCs meet T cells there

effector T cells migrate to graft

62
Q

describe antibody-mediated rejection

A
  • donor and recipient APCs migrate to 2ry lymphoid organs
  • APCs meet T cells there
  • T cells provide help to B cells
  • plasma cells develop
  • plama cells home to bone marrow
  • HLA Ab production
    -HLA Ab enters blood and reaches graft
  • effector T cells migrate to graft
63
Q

two types of antibody-mediated rejection

A

complement-mediated and
antibody-dependent cell-mediated cytotoxicity (ADCC)

64
Q

___ deposition is commonly observed in microvascular endothelium in aggressive ABMR

A

C4d; antibody-mediated rejection

65
Q

this type of rejection is very rare nowadays!

A

hyperacute rejection

66
Q

how to test patients for antibodies before transplantation

A
  • cells from donor
  • sera from patients
    = flow cytometry; if strong rxn = don’t transplant bc there might be Abs there
67
Q

highly sensitized patient registry in kidney transplantation: for patients with cPRA > ___%

A

95%
- deceased donor HLA entered into national registry
- kidneys may be offered across Canada

68
Q

T or F. There is no current assay that tests for memory B cells

A

T

69
Q

danger of memory in a transplant

A

when pts tested for Abs, memory B cells don’t come up
so when transplantation occurs (after crossmatch is “ok), it can incite an immune response = previously undetected Ab may elicit a memory response

maybe not exposed to exact antigen from donor but could have been exposed to HLA antigen from donor that shared same epitope as the antigen that elicited response

70
Q

diagnosis of rejection

A
  • initially non-specific = malaise, lethargy, apathy, weakness, discomfort, low creatinine clearance/proteinuria (kidney), etc.
  • Dx based on biopsy, blood test, and HLA Ab testing
71
Q

T or F. Chronic rejections can be asymptomatic

A

T

72
Q

HLA sensitization events

A

pregnancy
blood transfusion
previous transplants
cross-reactivity
any human tissue allografts (ex: ortho surgeries)

73
Q

issues with pre-transplant HLA antibody testing to preventing rejection

A

only addresses issues with pre-existing DSA/ hyperacute AMR

does NOT prevent development of new antibodies to the transplant

74
Q

Mechanisms of immunosuppression/ how does immunosuppression inhibit undesirable immunologic activity?

A

depletion of cells involved in immune response

inhibition of pathways required for the induction of an immune response

blocking of receptors

75
Q

broad spectrum immunosuppressive and anti-inflammatory effects

A

glucocorticosteroids

76
Q

glucocorticosteroids mechanism

A
  • interact with GRs found on most body cells = internalized by cell
  • down-reg of costim and adhesion molecules
  • donw-reg of inflammatory cytokines (IL-12…), up-reg of anti-inflam (IL-10)
77
Q

this is measured for small molecule drug levels

A

trough

78
Q

protein-based/biologic drugs (depleting Abs)

A

depleting Abs

rabbit polyclonal anti-thymocyte globulin (rATG)
=> polyclonal Abs to thymocytes; inducton therapy

Alemtuzumab (Campath)
=> monoclonal Abs to CD52; expressed on lymphocytes; induction therapy

Rituximab
=> monoclonal Abs to CD20, expressed on B cells (NOT on plasma cells); desensitization or rescue therapy

79
Q

protein-based/biologic drugs (non-depleting Abs)

A

Basiliximab
- Ab to IL-2 recptor alpha chain = CD25
- CD25 expressed on activated T cells = deceased cell activation
- does not cause T cell depletion
- induction therapy

80
Q

protein-based/biologic drugs (fusion protein)

A

CTLA-4 immunoglobulin
- Fc fragment of a human IgG1 Ig linked to extracell domain of CTLA-4
- blocks signal 2
- improper T cells activation
- maintenance therapy
- once/6 wks
- not commonly used

81
Q

advantages of protein-based/biologic drugs

A
  • high specificity (monoclonal and fusion esp.)
  • low toxicity, at least from agent itself
  • long half-life in circulation = same as IgG (~3 wks)
82
Q

disadvantages of protein-based/biologic drugs

A

some interfere with Ab detection assays and/or FCXM

EXPENSIVE!

83
Q

antibody removal methods

A
  • plasmapheresis: filters blood and removes harmful Abs
  • IVIg: pooled IgG from plasma of ~1000+ donors
    > inhibits antibody production, complement activation, immune cell activation
84
Q

Bortezomib

A
  • novel; protease inhibitor; small molecule
  • induce apoptosis of active plasma cells due to high amount of proteins produced by plasma cell
  • build up of misfolded proteins = apoptosis
  • rescue therapy
85
Q

Eculizumab

A
  • humanized monoclonal anti-C5; novel
  • prevents complement activation from classical/alt pathways by neutralizing C5
  • rescue therapy
86
Q

transplantation tolerance

A

absence of a destructive immune response to an allograft in an otherwise competent immune system = NO IMMUNOSUPPRESSION

87
Q

describe central tolerance

A

immunological tolerance to self antigens that is established while lymphocytes are developing in central lymphoid organs

  • Thymus: eliminate T cells with high affinity for self peptide:MHC complex
  • BM: eliminate B cells with high affinity for self molecules
88
Q

describe peripheral tolerance

A

immunological tolerance acquired by mature lymphocytes in the peripheral tissues

MLSCI 475 (22 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions